Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07123896
Starting soon Observational

Arrhythmia Cohort Study

NCT07123896 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Anzhen Hospital
Phase
Observational
Started
2025-08-24
Last updated
2025-08-14

Condition(s) studied

Arrhythmia

Investigational drug(s) / intervention(s)

Normal treatment with catheter ablation or medicineDrug Treatment

Normal treatment with catheter ablation or medicine: Routine clinical care with catheter ablation and/or medicine; real-world clinical cases

Drug Treatment: Routine clinical care with medicine; real-world clinical cases

Study summary

The goal of this prospective, observational registry study is to evaluate the long-term effectiveness, safety, and impact of different kinds of treatment on the quality of life across diverse arrhythmia subtypes and patient populations in hospitalized adults with cardiac arrhythmias (including atrial fibrillation, atrial flutter, supraventricular tachycardia, and ventricular arrhythmias) undergoing routine clinical care.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Patients hospitalized for any type of arrhythmia Exclusion Criteria: * Patients currently participating in interventional clinical trials that may confound data collection or outcome assessment in this study.

Primary outcome measure(s)

  • Arrhythmia recurrence — 1 year
    Recurrence of the arrhythmia after treatment
  • All-cause death — 1 year
    Death due to any reason

Trial sites (1)

FacilityCityRegionStatus
Deyong Long Beijing China

More Beijing Anzhen Hospital trials in China

Catheter Ablation of Haemodynamically Not-tolerated Electrical Storm in Structural Heart Disease Starting soon
Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation Active, not recruiting
Discontinuation of Anticoagulation With Intensive Rhythm Monitoring in Post-ablation Patients With Atrial Fibrillation Recruiting
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) Active, not recruiting
The Value of Novel Thrombus Markers in the Diagnosis and Treatment of Acute Pulmonary Embolism Active, not recruiting

Other trials for the same condition

Validation of the Accuracy of a Novel POCT Dry Electrolyte Analysis System in the Acute Care Setting Recruiting
Acute Cerebrovascular Events in Patients Undergoing Catheter Ablation Starting soon
Deep Learning for Intelligent Identification of Arrhythmias Starting soon
Electrophysiological Outcomes After Transcatheter Aortic Valve Replacement Active, not recruiting
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07123896 on ClinicalTrials.gov ↗ ← All trials in China